Patients who were at least 18 years of age were enrolled if they could undergo randomization within 12 hours after having an acute ischemic stroke with a score of 3 or less on the National Institutes of Health Stroke Scale (NIHSS) (scores range from 0 to 42, with higher scores indicating greater stroke severity) or a high-risk TIA with a score of 4 or more on the ABCD2 (link) scale14 (which estimates the risk of recurrent stroke after a TIA on the basis of age, blood pressure, clinical features, duration of symptoms, and presence of diabetes; scores ranges from 0 to 7, with higher scores indicating a greater risk of stroke). They were also required to undergo computed tomography or magnetic resonance imaging to rule out intracranial bleeding or other conditions that could explain the neurologic symptoms or detect any contraindications to a trial treatment. Patients with TIA and minor, nondisabling ischemic stroke are generally not considered to be candidates for thrombolysis or endovascular therapy.10 (link) Additional details regarding the inclusion and exclusion criteria are provided in the protocol.13 (link)Patients were ineligible if the symptoms of the initial TIA were limited to isolated numbness, isolated visual changes, or isolated dizziness or vertigo or if they had received any thrombolytic therapy within 1 week before the event. Patients were also ineligible if they were candidates for thrombolysis, endovascular therapy, or endarterectomy; had planned use of antiplatelet therapy or anticoagulation therapy (including those with presumed atrial fibrillation or cardiovascular disease, in whom anticoagulation would be indicated); had a contraindication to aspirin or clopidogrel; or had anticipated use of a nonsteroidal antiinflammatory drug for more than 7 days during the trial period. Written informed consent was required before the performance of any trial procedure.
>
Procedures
>
Therapeutic or Preventive Procedure
>
Thrombolytic Therapy
Thrombolytic Therapy
Thrombolytic Therapy is a medical intervention that utilizes pharmacological agents to dissolve or break up blood clots (thrombi) within the body.
This treatment approach is commonly used in the management of conditions such as acute myocardial infarction, ischemic stroke, and deep vein thrombosis.
The goal of Thrombolytic Therapy is to restore blood flow and prevent further tissue damage caused by the obstructed blood vessel.
Effecttive protocols for this therapy are crucial for ensuring optimal outcomes and reproducibility in clinical research and practice.
This treatment approach is commonly used in the management of conditions such as acute myocardial infarction, ischemic stroke, and deep vein thrombosis.
The goal of Thrombolytic Therapy is to restore blood flow and prevent further tissue damage caused by the obstructed blood vessel.
Effecttive protocols for this therapy are crucial for ensuring optimal outcomes and reproducibility in clinical research and practice.
Most cited protocols related to «Thrombolytic Therapy»
Acute Ischemic Stroke
Anti-Inflammatory Agents, Non-Steroidal
Aspirin
Atrial Fibrillation
Blood Pressure
Cardiovascular Diseases
Cerebrovascular Accident
Clopidogrel
Diabetes Mellitus
Endarterectomy
Fibrinolytic Agents
Neurologic Symptoms
Patients
Stroke, Ischemic
Therapeutics
Thrombolytic Therapy
Vertigo
X-Ray Computed Tomography
Attributes considered in designing a registry must ensure that data are valid, reliable, responsive, interpretable, and translatable
[37 ]. UTHSR is a prospective registry initially designed to capture essential information on all patients admitted to the UTHealth in-patient stroke service at MHH-TMC, with the primary aims of tracking the number of patients treated with intravenous (IV) tPA, their essential demographics, and complication rates, and to support research by members of the stroke team. With the funding of SPOTRIAS, the Principal Investigators (PIs) of the original SPOTRIAS sites decided to obtain common data elements that described essential demographics of all patients treated with IV tPA or enrolled in any clinical trials. UTHSR was consequently expanded to incorporate other elements including those variables that were needed for clinical trials that were conducted by the UT stroke team and variables that were needed for reporting to The Joint Commission (TJC)
[38 ,39 (link)], as well as select variables to meet minimum requirements for reporting to Centers for Medicare and Medicaid Services (CMS) as they pertain to the vascular neurology aspects of required reporting
[40 ]. All patients who have been admitted to the stroke unit at MHH-TMC are classified by stroke diagnosis subtypes, including infarct (non-hemorrhagic stroke), intracerebral hemorrhage (ICH), intraventricular hemorrhage (IVH), transient ischemic attack (TIA), subarachnoid hemorrhage (SAH), epidural hematomas (EDH), subdural hematomas (SDH), non-acute infarct, and others that could not be classified as any of the above (“Not stroke”), and are entered in UTHSR. Other data elements include admission information (e.g., arrival date and time), medical history, National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS) score, Glasgow Coma Scale (GCS), laboratory results, CT scan, CT scan angiogram, MRI, MR angiogram images, thrombolysis therapy (e.g., tPA time and door to needle time), intra-arterial therapy (IAT), complications, and discharge information including: death, mRS on discharge (or day 7, whichever comes first), discharge disposition (home, skilled nursing facility, etc.), and particularly patient education and mRS at 90 days. Currently, the UTHealth stroke team captures up to 235 variables for each patient depending on stroke subtypes. Since some of these variables have multiple responses (e.g., medical history), the number of fields in UTHSR is 372. As UTHSR is modified, corresponding changes to the codebook are made; the codebook is also updated periodically as changes to the abstraction rules are identified or where clarity can be improved. The data core has developed policies for documentation. Members of the data core are responsible for adhering to all policies and procedures established.
[37 ]. UTHSR is a prospective registry initially designed to capture essential information on all patients admitted to the UTHealth in-patient stroke service at MHH-TMC, with the primary aims of tracking the number of patients treated with intravenous (IV) tPA, their essential demographics, and complication rates, and to support research by members of the stroke team. With the funding of SPOTRIAS, the Principal Investigators (PIs) of the original SPOTRIAS sites decided to obtain common data elements that described essential demographics of all patients treated with IV tPA or enrolled in any clinical trials. UTHSR was consequently expanded to incorporate other elements including those variables that were needed for clinical trials that were conducted by the UT stroke team and variables that were needed for reporting to The Joint Commission (TJC)
[38 ,39 (link)], as well as select variables to meet minimum requirements for reporting to Centers for Medicare and Medicaid Services (CMS) as they pertain to the vascular neurology aspects of required reporting
[40 ]. All patients who have been admitted to the stroke unit at MHH-TMC are classified by stroke diagnosis subtypes, including infarct (non-hemorrhagic stroke), intracerebral hemorrhage (ICH), intraventricular hemorrhage (IVH), transient ischemic attack (TIA), subarachnoid hemorrhage (SAH), epidural hematomas (EDH), subdural hematomas (SDH), non-acute infarct, and others that could not be classified as any of the above (“Not stroke”), and are entered in UTHSR. Other data elements include admission information (e.g., arrival date and time), medical history, National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS) score, Glasgow Coma Scale (GCS), laboratory results, CT scan, CT scan angiogram, MRI, MR angiogram images, thrombolysis therapy (e.g., tPA time and door to needle time), intra-arterial therapy (IAT), complications, and discharge information including: death, mRS on discharge (or day 7, whichever comes first), discharge disposition (home, skilled nursing facility, etc.), and particularly patient education and mRS at 90 days. Currently, the UTHealth stroke team captures up to 235 variables for each patient depending on stroke subtypes. Since some of these variables have multiple responses (e.g., medical history), the number of fields in UTHSR is 372. As UTHSR is modified, corresponding changes to the codebook are made; the codebook is also updated periodically as changes to the abstraction rules are identified or where clarity can be improved. The data core has developed policies for documentation. Members of the data core are responsible for adhering to all policies and procedures established.
Angiography
Arteries
Blood Vessel
Cerebral Hemorrhage
Cerebrovascular Accident
Diagnosis
Education of Patients
Hematoma, Epidural, Cranial
Hematoma, Subdural
Hemorrhage
Hemorrhagic Stroke
Infarction
Joints
Needles
Patient Discharge
Patients
Subarachnoid Hemorrhage
Therapeutics
Thrombolytic Therapy
Transient Ischemic Attack
X-Ray Computed Tomography
Administrators
Ambulances
Biological Evolution
Hospital Referral
Medical Devices
Paramedical Personnel
Patient Transfer
Percutaneous Coronary Intervention
Physician Executives
ST Segment Elevation Myocardial Infarction
Thrombolytic Therapy
Discharge with ischemic stroke (IS), ICH (including non-traumatic subdural hematoma), and SAH were identified with KCD codes I63, I61-2, and I60, respectively. Use of intravenous thrombolysis (IVT) was identified with the drug code for rtPA since there is no procedure code for IVT in the Korean NHI claims data. IAT was identified using the procedure codes for percutaneous thrombolysis for the intracranial artery, percutaneous thrombolysis for other artery, and mechanical or aspiration thrombectomy (M6631, M6632, and M6633, respectively). The following European Cooperative Acute Stroke Study III criteria were used to detect symptomatic intracranial hemorrhage (SICH) following thrombolytic therapy: any apparently extravascular blood in the brain or within the cranium associated with a worsening of the National Institutes of Health Stroke Scale score of ≥4 or leading to death.18 (link)
Reviews of medical records and brain imaging or prospective stroke registry were considered the gold standards. In this study, stroke was defined as an acute neurological deficit caused by focal cerebral ischemia, brain parenchymal hemorrhage, or bleeding into the subarachnoid space.19 (link) Admissions with acute stroke were identified by limiting admissions to within 4 weeks of symptom onset. Three algorithms for stroke diagnoses were tested: 1) all available diagnoses up to nine positions, 2) one primary diagnosis and one secondary diagnosis, and 3) only one primary diagnosis. The sensitivity, specificity, positive predictive value (PPV), and agreement were calculated for each algorithm using a 2×2 table [hospital discharge data diagnosis (yes/no) versus gold standard diagnosis (yes/no)]. Finally, overall agreement was computed using all stroke subtypes (4×4 table) together for a given algorithm. The accuracies among different hospital departments were examined by performing the same analysis by discharge department. The degree of agreement, κ, was defined as substantial (0.61≤κ≤0.80) or almost perfect (0.81≤κ≤1.00).20 (link)
Reviews of medical records and brain imaging or prospective stroke registry were considered the gold standards. In this study, stroke was defined as an acute neurological deficit caused by focal cerebral ischemia, brain parenchymal hemorrhage, or bleeding into the subarachnoid space.19 (link) Admissions with acute stroke were identified by limiting admissions to within 4 weeks of symptom onset. Three algorithms for stroke diagnoses were tested: 1) all available diagnoses up to nine positions, 2) one primary diagnosis and one secondary diagnosis, and 3) only one primary diagnosis. The sensitivity, specificity, positive predictive value (PPV), and agreement were calculated for each algorithm using a 2×2 table [hospital discharge data diagnosis (yes/no) versus gold standard diagnosis (yes/no)]. Finally, overall agreement was computed using all stroke subtypes (4×4 table) together for a given algorithm. The accuracies among different hospital departments were examined by performing the same analysis by discharge department. The degree of agreement, κ, was defined as substantial (0.61≤κ≤0.80) or almost perfect (0.81≤κ≤1.00).20 (link)
Acute Cerebrovascular Accidents
Alteplase
Arteries
Aspiration Thrombectomy
BLOOD
Brain
Cerebral Ischemia
Cerebrovascular Accident
Cranium
Diagnosis
Europeans
Fibrinolytic Agents
Gold
Hemorrhage, Brain
Hypersensitivity
Intracranial Hemorrhage
Koreans
Patient Discharge
Pharmaceutical Preparations
Stroke, Ischemic
Subarachnoid Space
Subdural Hematoma, Traumatic
Thrombolytic Therapy
BLOOD
Healthy Volunteers
Homo sapiens
Phosphates
Saline Solution
Serum Albumin, Bovine
Thrombolytic Therapy
Most recents protocols related to «Thrombolytic Therapy»
Study type: published Observational study;
Subjects: patients diagnosed with ACI according to the diagnostic criteria of the Cerebrovascular Group, Chinese Society of Neurology, Chinese medical association, and the American heart association/American stroke association.[19 ,20 (link)] There were no restrictions on age, gender, or the source of medical records for the study subjects;
Intervention measures: the treatment group was treated with NBP injection alone or in combination with conventional treatment with Western medicine or thrombolytic therapy;
The control group received only conventional treatment with Western medicine or thrombolytic therapy;
Outcome indicators: C-reactive protein (CRP); superoxide dismutase (SOD) levels; malondialdehyde (MDA) levels; vascular endothelial growth factor (VEGF) levels; endothelin-1 (ET-1) levels; nitric oxide (NO) levels; cerebral infarct volume CIV; cerebral infarct size (CIS); and Adverse reaction ratio.
Subjects: patients diagnosed with ACI according to the diagnostic criteria of the Cerebrovascular Group, Chinese Society of Neurology, Chinese medical association, and the American heart association/American stroke association.[19 ,20 (link)] There were no restrictions on age, gender, or the source of medical records for the study subjects;
Intervention measures: the treatment group was treated with NBP injection alone or in combination with conventional treatment with Western medicine or thrombolytic therapy;
The control group received only conventional treatment with Western medicine or thrombolytic therapy;
Outcome indicators: C-reactive protein (CRP); superoxide dismutase (SOD) levels; malondialdehyde (MDA) levels; vascular endothelial growth factor (VEGF) levels; endothelin-1 (ET-1) levels; nitric oxide (NO) levels; cerebral infarct volume CIV; cerebral infarct size (CIS); and Adverse reaction ratio.
Cerebral Infarction
Cerebrovascular Accident
Chinese
C Reactive Protein
Diagnosis
Endothelin-1
Gender
Malondialdehyde
Oxide, Nitric
Patients
Pharmaceutical Preparations
Stroke Volume
Superoxide Dismutase
Thrombolytic Therapy
Vascular Endothelial Growth Factors
Study materials were collected from the Suzhou Taicang Hospital of Traditional Chinese Medicine from November 2020 to August 2022. There were 178 cases where a diagnosis of AIS was made. The ethics committee of the Suzhou Taicang Hospital of Traditional Chinese Medicine approved this study and waived patient consent due to the retrospective study design (Grant No. 2022-023). All study procedures were carried out in accordance with the relevant guidelines and regulations.
Among these 178 cases, 57 patients who met the following criteria at our institution were retrospectively included in this study: (1) all patients clinically diagnosed with AIS had undergone one-stop, plain CT scan, CTP, and CTA, (2) all scans were performed within the 24 h of the onset of AIS, (3) all data had undergone valid quantitative analysis by F-STROKE (16 (link)), an automated perfusion analysis software (version 1.0.18; Neuroblast, Ltd. Co.), (4) all diagnostic images were clear, with no obvious motion artifacts or metallic artifacts evident, (5) no other brain diseases, such as brain tumors, vascular malformations, or cerebral hemorrhages, and (6) no previous history of thrombolytic therapy or massive cerebral infarction. Exclusion criteria included (1) the time of onset was >24 h, (2) the quantitative value was too small (ischaemic focus range: <5 mL), as determined using the F-STROKE software, (3) a history of thrombolytic therapy or massive cerebral infarction, (4) brain tumor or cerebrovascular disease, or (5) CT image quality did not meet the evaluation requirements (e.g., based on the presence of titanium clip artifacts or heavy motion artifacts). A flow chart of the inclusion/exclusion process is displayed inFigure 1 . The CTA showed corresponding stenosis or occlusion in 50 cases and was normal in 7 cases.
Among these 178 cases, 57 patients who met the following criteria at our institution were retrospectively included in this study: (1) all patients clinically diagnosed with AIS had undergone one-stop, plain CT scan, CTP, and CTA, (2) all scans were performed within the 24 h of the onset of AIS, (3) all data had undergone valid quantitative analysis by F-STROKE (16 (link)), an automated perfusion analysis software (version 1.0.18; Neuroblast, Ltd. Co.), (4) all diagnostic images were clear, with no obvious motion artifacts or metallic artifacts evident, (5) no other brain diseases, such as brain tumors, vascular malformations, or cerebral hemorrhages, and (6) no previous history of thrombolytic therapy or massive cerebral infarction. Exclusion criteria included (1) the time of onset was >24 h, (2) the quantitative value was too small (ischaemic focus range: <5 mL), as determined using the F-STROKE software, (3) a history of thrombolytic therapy or massive cerebral infarction, (4) brain tumor or cerebrovascular disease, or (5) CT image quality did not meet the evaluation requirements (e.g., based on the presence of titanium clip artifacts or heavy motion artifacts). A flow chart of the inclusion/exclusion process is displayed in
Brain Diseases
Brain Neoplasms
Cerebral Hemorrhage
Cerebral Infarction
Cerebrovascular Accident
Cerebrovascular Disorders
Clip
Dental Occlusion
Diagnosis
Ethics Committees, Clinical
Metals
Patients
Perfusion
Radionuclide Imaging
Stenosis
Thrombolytic Therapy
Titanium
Vascular Malformations
X-Ray Computed Tomography
We retrospectively reviewed the data of 211 patients with PBSH from 342 consecutive patients admitted to our institution between January 2014 and October 2020. The inclusion criteria were as follows: (1) a diagnosis of PBSH confirmed by CT and (2) complete clinical data (laboratory data, imaging data, and other clinical data). The exclusion criteria were as follows: (1) secondary brainstem hemorrhage caused by trauma, thrombolytic therapy, cavernous hemangioma, or arteriovenous malformation, (2) surgical treatment of brainstem hemorrhage before admission to our hospital, (3) admission to our hospital more than 10 days after symptom onset, and (4) missed follow-up.
Arteriovenous Malformation
Brain Stem
Diagnosis
Hemangioma, Cavernous
Hemorrhage
Operative Surgical Procedures
Patients
Surgical Blood Losses
Thrombolytic Therapy
Wounds and Injuries
The diagnosis criteria for AMI were based on the 2012 ESC/AHA/ACC guidelines.17 (link) Specific details are as follows: (a) the cTn level should be 99% higher than the upper limit reference value; (b) significant changes in the ST-T stage or left bundle branch block; (c) obvious symptoms of ischemia in electrocardiogram; (d) coronary thrombosis in angiography; and (e) loss of viable heart muscle or abnormal ventricular wall. Patients who had received anticoagulation or thrombolytic therapy and patients with other comorbidities or organ failures were excluded. Healthy individuals without a history of cardiovascular diseases and thrombolytics were included.
According to the above criteria, a total of 83 AMI patients and 62 healthy individuals were included in this study from June 2019 to June 2020. Approval was obtained from the ethics committee of Beijing JiShuiTan Hospital. The procedures used in this study adhere to the tenets of the Declaration of Helsinki. All participants had signed the informed consent. The AMI patients were followed up for 6 months after corresponding treatments. The cardiovascular events and all cause-induced deaths were defined as the endpoints.
According to the above criteria, a total of 83 AMI patients and 62 healthy individuals were included in this study from June 2019 to June 2020. Approval was obtained from the ethics committee of Beijing JiShuiTan Hospital. The procedures used in this study adhere to the tenets of the Declaration of Helsinki. All participants had signed the informed consent. The AMI patients were followed up for 6 months after corresponding treatments. The cardiovascular events and all cause-induced deaths were defined as the endpoints.
Angiography
Cardiovascular Diseases
Cardiovascular System
Coronary Angiography
Coronary Thrombosis
Diagnosis
Electrocardiography
Ethics Committees, Clinical
Fibrinolytic Agents
Heart Ventricle
Ischemia
Left Bundle-Branch Block
Myocardium
Patients
Thrombolytic Therapy
Thrombosis
We enrolled 930 ischemic stroke patients with thrombolytic therapy within 6 h of the stroke onset from July 2018 to June 2020 retrospectively in two stroke centers in the local hospital, whose age ranged from 18 to 80 years and head computed tomography (CT) scans showed no acute hemorrhage. Twelve patients with missing clinical data were excluded. For stroke patients with an onset within 4.5 h, rtPA was directly delivered, and for patients whose onset was 4.5–6 h, rtPA was not given until magnetic resonance imaging (MRI) showing new infarction area. The comprehensive treatments for these patients in two centers were consistent and based on both European stroke organizations (ESO) guidelines on intravenous thrombolysis (Berge et al., 2021 (link)) and Chinese guidelines.
The mRs system was used to evaluate the neurological outcome at 3 months after the thrombolysis for these patients, and mRs < 2 was considered as a favorable neurological outcome, while mRs 2–6 was poor outcome. This study was approved by the Ethical Board of Shanghai Pudong New Area People’s Hospital with a waiver of informed consent due to the retrospective nature of the study. Informed consent for intravenous thrombolysis was obtained from all patients.
The mRs system was used to evaluate the neurological outcome at 3 months after the thrombolysis for these patients, and mRs < 2 was considered as a favorable neurological outcome, while mRs 2–6 was poor outcome. This study was approved by the Ethical Board of Shanghai Pudong New Area People’s Hospital with a waiver of informed consent due to the retrospective nature of the study. Informed consent for intravenous thrombolysis was obtained from all patients.
Alteplase
Cerebrovascular Accident
Chinese
Europeans
Fibrinolytic Agents
Head
Hemorrhage
Infarction
Patients
Radionuclide Imaging
Stroke, Ischemic
Thrombolytic Therapy
X-Ray Computed Tomography
Top products related to «Thrombolytic Therapy»
Sourced in Germany, France
Actilyse is a laboratory equipment product manufactured by Boehringer Ingelheim. It is a recombinant tissue plasminogen activator (rt-PA) used for the in vitro analysis of fibrinolytic systems.
Sourced in Germany
Rt-PA is a laboratory equipment product used in research applications. It is a recombinant tissue plasminogen activator, a protein that plays a role in the breakdown of blood clots. The core function of Rt-PA is to facilitate the conversion of plasminogen to plasmin, which is an enzyme involved in the dissolution of fibrin clots.
Sourced in Germany
Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It functions to dissolve blood clots by activating plasminogen, which then converts fibrin into soluble fragments.
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
Sourced in United States, Germany, United Kingdom, Canada, Macao, Japan, France, Switzerland, Hungary, Italy, China
Fibrinogen is a plasma protein that plays a crucial role in the blood clotting process. It is a component of the coagulation cascade and is essential for the formation of fibrin clots.
Sourced in United States, Austria, Germany, Poland, United Kingdom, Canada, Japan, Belgium, China, Lao People's Democratic Republic, France
Prism 9 is a powerful data analysis and graphing software developed by GraphPad. It provides a suite of tools for organizing, analyzing, and visualizing scientific data. Prism 9 offers a range of analysis methods, including curve fitting, statistical tests, and data transformation, to help researchers and scientists interpret their data effectively.
Sourced in United States, United Kingdom, Brazil, Germany, Canada, France, Spain, Italy, Switzerland, Australia, Sweden, Belgium, New Zealand, Denmark, Mexico, Jersey, South Sudan, Austria, Japan
The BD Vacutainer is a blood collection system used to collect, process, and preserve blood samples. It consists of a sterile evacuated glass or plastic tube with a closure that maintains the vacuum. The Vacutainer provides a standardized method for drawing blood samples for laboratory analysis.
Sourced in United States, Germany, United Kingdom, China, Sao Tome and Principe, Switzerland, Sweden, Ireland, Macao, India, Australia, France, Spain
Thrombin is a serine protease enzyme that plays a crucial role in the blood coagulation process. It is responsible for the conversion of fibrinogen to fibrin, which is the main structural component of blood clots. Thrombin also activates other factors involved in the clotting cascade, promoting the formation and stabilization of blood clots.
Sourced in Germany, United States, China, Japan
The Genomic DNA purification kit is a laboratory tool designed to extract and purify high-quality genomic DNA from a variety of biological samples. The kit employs a standardized process to efficiently isolate DNA, making it suitable for downstream applications such as PCR, sequencing, and other molecular biology techniques.
Sourced in Japan
The SH-1000Lab is a piece of laboratory equipment used for the measurement and analysis of various samples. It is designed to perform specific functions within a controlled laboratory environment.
More about "Thrombolytic Therapy"
Thrombolytic Therapy, also known as fibrinolytic therapy or clot-busting treatment, is a medical intervention that utilizes pharmacological agents to dissolve or break up blood clots (thrombi) within the body.
This treatment approach is commonly used in the management of conditions such as acute myocardial infarction (heart attack), ischemic stroke, and deep vein thrombosis.
The goal of Thrombolytic Therapy is to restore blood flow and prevent further tissue damage caused by the obstructed blood vessel.
This is typically achieved through the use of thrombolytic agents like Actilyse (alteplase, recombinant tissue plasminogen activator or rt-PA), which work by activating the body's natural fibrinolytic system to break down the fibrin in the clot.
Effective protocols for this therapy are crucial for ensuring optimal outcomes and reproducibility in clinical research and practice.
Researchers may utilize tools like SAS 9.4 and Prism 9 to analyze data and develop the most effective Thrombolytic Therapy solutions.
In addition to pharmacological agents, Thrombolytic Therapy may also involve the use of laboratory tests and equipment, such as BD Vacutainer blood collection systems, genomic DNA purification kits, and coagulation assays to measure fibrinogen and thrombin levels.
Careful monitoring and adjustment of these parameters can help ensure the safety and efficacy of the treatment.
By leveraging the power of AI-driven comparison tools like PubCompare.ai, researchers can discover the optimal research protocols for Thrombolytic Therapy, locating and identifying the best protocols across literature, pre-prints, and patents.
This helps to ensure reproducibility and accuracy in their research, ultimately leading to improved patient outcomes.
This treatment approach is commonly used in the management of conditions such as acute myocardial infarction (heart attack), ischemic stroke, and deep vein thrombosis.
The goal of Thrombolytic Therapy is to restore blood flow and prevent further tissue damage caused by the obstructed blood vessel.
This is typically achieved through the use of thrombolytic agents like Actilyse (alteplase, recombinant tissue plasminogen activator or rt-PA), which work by activating the body's natural fibrinolytic system to break down the fibrin in the clot.
Effective protocols for this therapy are crucial for ensuring optimal outcomes and reproducibility in clinical research and practice.
Researchers may utilize tools like SAS 9.4 and Prism 9 to analyze data and develop the most effective Thrombolytic Therapy solutions.
In addition to pharmacological agents, Thrombolytic Therapy may also involve the use of laboratory tests and equipment, such as BD Vacutainer blood collection systems, genomic DNA purification kits, and coagulation assays to measure fibrinogen and thrombin levels.
Careful monitoring and adjustment of these parameters can help ensure the safety and efficacy of the treatment.
By leveraging the power of AI-driven comparison tools like PubCompare.ai, researchers can discover the optimal research protocols for Thrombolytic Therapy, locating and identifying the best protocols across literature, pre-prints, and patents.
This helps to ensure reproducibility and accuracy in their research, ultimately leading to improved patient outcomes.